



Press release from Emotra AB (publ)
Göteborg, December 29, 2020

Overview of our research and development activities in 2021

As for many other companies, the Covid-19 situation has been challenging for Emotra. The work on our clinical study and technical development of EDOR will gradually continue, while the recent acceptance for publication of a scientific paper is expected to boost our progress in 2021.

Like many other companies, Emotra has faced the challenges that Covid-19 brought with it. Operational delays have mostly affected ongoing clinical research collaboration projects. However, most of these projects should be seen as investments in activities that will bear fruit once the situation has improved.

Despite last year's challenges, the company has continued to move towards a network organisation comprised of a number of experts on clinical studies and to plan for the execution of our own clinical study on depression relapse. On December 21, 2020, Emotra announced that a manuscript with our first clinical findings, which our depression relapse track is based on, has been accepted for publication. It is the company's opinion that this publication will facilitate our work in the future. Our collaboration with our new partners in Germany has also generated a number of valuable contacts and opened up new possibilities that we expect will contribute positively to our progress in 2021.

Our project for digitalisation of the EDOR test showed strong potential over the past autumn, and we have made a lot of progress in a short period of time. Since this development concerns the company's main product, we are working incrementally in order to secure functionality and security, as well as enable the company to choose the right path for the future.

All in all, this year of the Corona pandemic has been challenging and has delayed some of our operations. However, we have put a lot of effort into groundwork that we should be able to build upon in 2021.

For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail:
daniel@emotra.se

Fel! Hittar inte referenskälla.

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.

Emotra AB (publ), AstraZeneca BioVentureHub, Pepparedsleden 1,
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93 www.emotra.se